Insider Trading February 4, 2026

Lemonade CEO Executes $902K Share Sale as Stock Pulls Back Ahead of Key Dates

Daniel Schreiber sold 9,108 shares under a 10b5-1 plan; warrant expirations and an upcoming earnings report remain on the calendar

By Maya Rios LMND
Lemonade CEO Executes $902K Share Sale as Stock Pulls Back Ahead of Key Dates
LMND

Lemonade CEO Daniel A. Schreiber sold 9,108 shares on January 23, 2026, for roughly $902,056 under a pre-arranged Rule 10b5-1 plan. The stock traded at $99.04 at the time - close to its 52-week high - and has since retreated to $74.18. The company faces several near-term events, including an earnings release and the scheduled expiration of warrants tied to its Metromile acquisition.

Key Points

  • CEO Daniel A. Schreiber sold 9,108 Lemonade shares on January 23, 2026, for about $902,056 under a Rule 10b5-1 plan.
  • LMND traded at $99.04 at the time of the sale - near its 52-week high of $99.90 - and has since declined to $74.18, with an 18.7% drop over the past week.
  • Near-term items include a February 19, 2026 earnings report and the February 9, 2026 expiration of 7,846,646 warrants tied to the Metromile acquisition; the NYSE will suspend warrant trading on February 5, 2026.

Transaction details

On January 23, 2026, Lemonade Inc. (NASDAQ: LMND) Chief Executive Officer Daniel A. Schreiber sold 9,108 shares of the company’s common stock for approximately $902,056. The shares were disposed at a price of $99.04, a level that nearly matched the stock’s 52-week high of $99.90.

Holding position after sale

Following the transaction, Schreiber continues to hold 1,514,426 Lemonade shares directly through Dan and Dan Ltd. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Schreiber adopted on December 11, 2024.

Market movement since the sale

Since the January 23 sale, LMND has fallen to $74.18. The report notes that the stock registered an 18.7% decline over the past week. Over longer horizons, Lemonade’s share price has shown pronounced volatility - the company has returned 112% over the past year and 54.8% over the last six months, and the stock’s beta is reported at 2.05.

Corporate developments and product initiatives

Separately, Lemonade has rolled out a new insurance product designed for Tesla vehicles equipped with Full Self-Driving (FSD) technology. Developed in collaboration with Tesla, the offering is structured to reduce per-mile rates by about 50% when FSD is engaged, based on data the company says shows lower risk during autonomous driving.

Analyst coverage and price targets

Recent analyst activity includes Truist Securities initiating coverage on Lemonade with a Buy rating and a $98 price target, citing the company’s digital-first model. Keefe, Bruyette & Woods adjusted its price target higher from $35 to $40, noting favorable loss trends while maintaining an Underperform rating.

Warrants and exchange actions

In addition to the other items noted, Lemonade announced the expiration of 7,846,646 warrants tied to its Metromile acquisition, scheduled for February 9, 2026. The New York Stock Exchange will suspend trading of those warrants on February 5, 2026, to facilitate settlement.

Upcoming calendar item

Investors tracking the company should note Lemonade’s upcoming earnings report, which is scheduled for February 19, 2026.


What this episode shows

The transaction is an example of an insider sale executed under a pre-established trading plan, occurring near a multi-week high, followed by a material pullback in share price and several corporate milestones that could affect near-term trading dynamics.

Risks

  • Significant recent price volatility - LMND has a reported beta of 2.05 and an 18.7% one-week drop - posing market risk for equity holders; impacts equities and financial markets.
  • The scheduled expiration of 7,846,646 Metromile-related warrants and the NYSE suspension of warrant trading could affect settlement mechanics and short-term liquidity; impacts capital markets and corporate finance.
  • An upcoming earnings report on February 19, 2026, introduces typical event risk around company fundamentals and short-term share-price movement; impacts investors and the insurance sector.

More from Insider Trading

UroGen CMO Sells Stock to Cover RSU Taxes as Company Reports Q3 Miss Feb 4, 2026 Adaptive Biotechnologies CEO Disposes $2.3M in Shares as Firm Posts Strong 2025 Results Feb 4, 2026 Sionna Therapeutics Director Disposes $1.37M in Shares as Analysts Diverge on Outlook Feb 4, 2026 Adaptive Biotechnologies CSO Disposes $799K in Stock Amid Strong 2025 Results Feb 4, 2026 Tango Therapeutics CFO Sells 10,317 Shares to Cover RSU Taxes; Company Boosts Liquidity and Leadership Shifts Announced Feb 4, 2026